SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.

Judit HodreaAdar SaeedAgnes MolnarAttila FinthaAdrienn BarcziLaszlo Jozsef WagnerAttila J SzaboAndrea FeketeDora Bianka Balogh

Published in: PloS one (2022)

These data support the preventive and protective role of SGLT2i in diabetes-associated cardiovascular disease. SGLT2i may provide novel therapeutic strategy to hinder the development of cardiovascular diseases in type 1 diabetes, thereby improve the outcomes.

Keyphrases

cardiovascular disease
type diabetes
glycemic control
cardiovascular events
cardiovascular risk factors
left ventricular
risk factors
electronic health record
big data
skeletal muscle
adipose tissue
coronary artery disease
machine learning